Does anyone know when imports go missing? 

Australia’s medicinal cannabis import framework lacks a clear line of sight from border entry to patient supply, according to ECS Botanics managing director Nan-Maree Schoerie. In this guest post, she argues stronger oversight of imported products is needed to reduce diversion risks and create a more balanced regulatory environment.

The Therapeutic Goods Administration’s (TGA) recent focus on unapproved peptides is a timely reminder of the risks posed by unregulated therapeutic products entering Australia through online, black-market and grey-market channels.